Doximity (DOCS) stock closed at $43.53, down 3.22% from the previous day. The stock underperformed the S&P 500, which gained 0.46%, while the Dow and Nasdaq rose 0.17% and 0.57%, respectively. In the past month, DOCS fell 9.95%, trailing the Medical sector’s 1.59% gain and the S&P 500’s 4.22% increase.

Market watchers await Doximity’s financial results, expecting an EPS of $0.44, a 2.22% drop from last year. Revenue is projected to reach $181.03 million, up 7.37% from the same quarter in the previous year. For the fiscal year, earnings estimates are $1.56 per share and revenue estimates are $645.29 million, up 9.86% and 13.13% respectively.

Doximity’s Zacks Rank of #3 (Hold) is influenced by estimated revisions, reflecting analysts’ sentiment towards the company’s performance. The Zacks Rank model, ranging from #1 to #5, considers estimate changes to determine actionable ratings. Notably, there has been a 0.78% increase in the Zacks Consensus EPS estimate over the past month.

With a Forward P/E ratio of 28.75, Doximity is trading at a discount compared to the industry average of 46.25. The stock’s PEG ratio stands at 1.52, while the Medical Info Systems industry has an average PEG ratio of 3.49. The industry ranks in the top 42% of all industries, as per the Zacks Industry Rank evaluation system.

Read more at Nasdaq: Doximity (DOCS) Stock Falls Amid Market Uptick: What Investors Need to Know